Genzyme Escapes Investor Class Action Over Stock Plunge

By Kurt Orzeck (June 5, 2014, 8:26 PM EDT) -- The First Circuit refused Thursday to revive a consolidated class action accusing Genzyme Corp. of misleading the U.S. Food and Drug Administration over manufacturing plant problems and selling its securities at artificially inflated prices, ruling the allegations didn't sufficiently show deceitful intent....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!